Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 125, Issue 12, Pages 2970-2977Publisher
WILEY
DOI: 10.1002/ijc.24659
Keywords
Single-walled carbon nanotube; monoclonal antibody; near-infrared thermal ablation; cancer therapy
Categories
Funding
- Cancer Immunobiology Center
- DOD [W81XWH-08-2-000]
- Norman Hackerman Texas Advanced Research (Biological Sciences) Program [009741-0005-2007]
- Robert A. Welch Foundation [AT-1364, AT-1326]
Ask authors/readers for more resources
CD22 is broadly expressed on human B cell lymphomas. Monoclonal anti-CD22 antibodies alone, or coupled to toxins, have been used to selectively target these tumors both in SCID mice with xenografted human lymphoma cell lines and in patients with B cell lymphomas. Single-walled carbon nanotubes (CNTs) attached to antibodies or peptides represent another approach to targeting cancer cells. CNTs convert absorbed near-infrared (NIR) light to heat, which can thermally ablate cells that have bound the CNTs. We have previously demonstrated that monoclonal antibodies (MAbs) noncovalently coupled to CNTs can specifically target and kill cells in vitro. Here, we describe the preparation of conjugates in which the MAbs are covalently conjugated to the CNTs. The specificity of both the binding and NIR-mediated killing of the tumor cells by the MAb-CNTs is demonstrated by using CD22(+)CD25(-) Daudi cells, CD22(-)CD25(+) phytohemagglutinin-activated normal human peripheral blood mononuclear cells, and CNTs covalently modified with either anti-CD22 or anti-CD25. We further demonstrate that the stability and specificity of the MAb-CNT conjugates are preserved following incubation in either sodium dodecyl sulfate or mouse serum, indicating that they should be stable for in vivo use. (C) 2009 UICC
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available